patient_id,study_id,tp53_mut,pik3ca_mut,erbb2_mut,esr1_mut,brca1_mut,brca2_mut,top1_mut,adc_resistance_risk,adc_resistance_score,adc_resistance_rationale,sg_cross_resistance_risk,sg_cross_resistance_score,sg_cross_resistance_rationale,endocrine_sensitivity,endocrine_sensitivity_score,endocrine_sensitivity_rationale,eribulin_sensitivity,eribulin_sensitivity_score,eribulin_sensitivity_rationale
TCGA-3C-AAAU,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-3C-AALI,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,1,TOP2A mutation,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-3C-AALJ,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-3C-AALK,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-4H-AAAK,brca_tcga_pan_can_atlas_2018,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-5L-AAT0,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A1-A0SD,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A1-A0SF,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A1-A0SG,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A1-A0SH,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A1-A0SI,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,1.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A1-A0SK,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A1-A0SO,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A1-A0SP,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A1-A0SQ,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A04N,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A04P,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,1.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A04Q,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A04T,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A04U,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A04V,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A04W,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0CL,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0CM,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0CP,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0CR,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0CS,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0CV,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0CW,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0CX,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,1,TOP2A mutation,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0CZ,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0D0,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0D1,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0D2,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0D3,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0EM,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0EN,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0EO,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0EQ,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0EU,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0EV,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0EW,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0EX,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0EY,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0ST,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0SU,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0SV,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0SW,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0SX,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0SY,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0T0,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0T1,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0T2,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0T3,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0T4,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0T5,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0T6,brca_tcga_pan_can_atlas_2018,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0T7,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0YC,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0YD,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0YE,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0YF,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0YG,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0YH,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0YI,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0YJ,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0YK,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0YL,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A0YM,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A0YT,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A1FZ,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A1G0,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A1G1,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A259,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A25A,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A25B,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A25C,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A25D,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A3XT,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A3XV,brca_tcga_pan_can_atlas_2018,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A3XX,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A3Y0,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A4S1,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A2-A4S2,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A2-A4S3,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A0CE,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A0CG,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A0CH,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A0CJ,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A0D9,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A0DA,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A0DB,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A13D,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A13E,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A13G,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A26E,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A26F,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A26G,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A26H,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,1.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A26I,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A2KD,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A3RF,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A4SC,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A4SD,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A4SE,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A56D,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A5ZV,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A5ZW,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A5ZX,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A7-A6VV,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A6VW,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A6VX,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A7-A6VY,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A8-A06O,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A8-A06P,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A8-A06Q,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A8-A06R,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A8-A06T,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A8-A06U,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A8-A06X,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A8-A06Y,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A8-A06Z,brca_tcga_pan_can_atlas_2018,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A8-A075,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A8-A076,brca_tcga_pan_can_atlas_2018,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
TCGA-A8-A079,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A8-A07B,brca_tcga_pan_can_atlas_2018,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
TCGA-A8-A07C,brca_tcga_pan_can_atlas_2018,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
TCGA-A8-A07E,brca_tcga_pan_can_atlas_2018,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0002,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0005,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0006,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0008,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0010,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0014,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0022,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0025,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0028,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0035,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0039,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0046,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0054,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0056,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0060,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0062,brca_metabric,1.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0066,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0068,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0079,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0081,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0083,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0093,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0095,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0097,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0100,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0101,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0102,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0106,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0107,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0108,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0109,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0111,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0114,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0115,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0121,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0122,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0124,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0125,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0127,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0128,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0131,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0133,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0136,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0138,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0139,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0143,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0144,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0145,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0147,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0148,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0149,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0150,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0152,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0154,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0157,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0162,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0163,brca_metabric,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0164,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0165,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0166,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0167,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0168,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0170,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0171,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0172,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0174,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0177,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0178,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0180,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0181,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0188,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0189,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0191,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0193,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0194,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0198,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0200,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0201,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0202,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0204,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0205,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0206,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0207,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0211,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0214,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0215,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0218,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0221,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0222,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0223,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0224,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0226,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0227,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0228,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0229,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0230,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0231,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0232,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0233,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0234,brca_metabric,0.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0235,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0236,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0238,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0239,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0241,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0242,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0243,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0245,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0247,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0249,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0256,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0257,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0258,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0259,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0261,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0262,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0265,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0266,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0268,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0270,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0272,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0273,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0278,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0279,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0282,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0284,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0285,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0286,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0288,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0290,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0292,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0294,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0295,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0301,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0302,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0303,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0304,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0305,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0306,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0308,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0309,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0310,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0311,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0313,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0314,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0315,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0316,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0317,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0320,brca_metabric,0.0,1.0,0.0,0,1.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0321,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0322,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0324,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0325,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0326,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0328,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0340,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0341,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0342,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0344,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0345,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0346,brca_metabric,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0348,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0349,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0350,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0353,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0354,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0356,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0358,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0359,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0360,brca_metabric,0.0,1.0,0.0,0,0.0,1.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0361,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0362,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0363,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0364,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0365,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0366,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0372,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0373,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0374,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0375,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0377,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0378,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0379,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0380,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0381,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0382,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0383,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0384,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0386,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0388,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0389,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0391,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0392,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0393,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0394,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0395,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0396,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0397,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0398,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0399,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0400,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0401,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0402,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0406,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0410,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0411,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0412,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0414,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0417,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0418,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0419,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0420,brca_metabric,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0421,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0422,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0425,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0426,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0429,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0431,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0434,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0436,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0438,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0440,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0442,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0443,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0446,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0449,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0451,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0452,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0453,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0455,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0458,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0459,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0462,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0463,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0464,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0465,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0466,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0467,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0469,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0470,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0471,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0472,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0474,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0475,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0476,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0478,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0479,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0480,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0481,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0482,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0483,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0484,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0485,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0486,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0487,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0489,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0490,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0491,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0494,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0495,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0496,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0497,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0500,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0501,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0504,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0505,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0506,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0509,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0511,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0512,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0513,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0514,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0516,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0517,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0519,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0522,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0524,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0525,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0528,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0529,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0532,brca_metabric,0.0,1.0,0.0,0,1.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0534,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0535,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0536,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0537,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0545,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0547,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0550,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0551,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0552,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0554,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0558,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0559,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0568,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0569,brca_metabric,0.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0570,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0571,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0574,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0575,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0576,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0577,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0578,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0579,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0580,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0581,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0582,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0583,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0584,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0585,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0587,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0588,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0589,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0591,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0593,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0594,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0596,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0597,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0598,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0601,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0603,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0605,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0607,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0608,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0609,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0611,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0613,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0615,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0616,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0618,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0621,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0623,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0624,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0626,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0627,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0630,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0631,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0632,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0636,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0637,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0638,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0639,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0640,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0642,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0643,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0644,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0646,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0649,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0650,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0652,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0653,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0654,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0655,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0656,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0657,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0658,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0660,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0662,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0663,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0664,brca_metabric,1.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0666,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0869,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0872,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0874,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0877,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-0880,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0882,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0884,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0891,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0895,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0897,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0899,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0901,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-0904,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-0906,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2513,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2517,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2536,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2564,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2610,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2614,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2616,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2617,brca_metabric,1.0,1.0,0.0,0,1.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2618,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2624,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2629,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2632,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2642,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2645,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2669,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2705,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2708,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2711,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2712,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2718,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2721,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2725,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2728,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2730,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2735,brca_metabric,0.0,1.0,0.0,0,1.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2742,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2744,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2745,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2747,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2749,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2750,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2752,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2753,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2758,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2760,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2763,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2765,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2767,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2771,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2772,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2774,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2778,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2779,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2781,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2786,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2790,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2791,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2793,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2796,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2801,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2803,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2814,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2815,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2819,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2820,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2823,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2827,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2833,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2834,brca_metabric,1.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2835,brca_metabric,0.0,1.0,0.0,0,0.0,1.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2838,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2840,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2842,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2843,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2844,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2845,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2846,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2847,brca_metabric,1.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2848,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2849,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2850,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2851,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2853,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2854,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2857,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2858,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2863,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2867,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2895,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2896,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2900,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2901,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2904,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2912,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2916,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2917,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2919,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2922,brca_metabric,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2923,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2927,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2929,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2931,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2933,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2939,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2944,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2947,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2951,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2952,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2953,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2957,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2960,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2963,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2964,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-2966,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2969,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2970,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2971,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2977,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2983,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2984,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-2990,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-2996,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3001,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3002,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3005,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3006,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3007,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3008,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3013,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3014,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3016,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3021,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3025,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3026,brca_metabric,0.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3028,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3032,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3033,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3035,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3037,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3046,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3049,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3050,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3057,brca_metabric,1.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3060,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3062,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3063,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3064,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3067,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3079,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3088,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3104,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3105,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3110,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3122,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3123,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3153,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3165,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3167,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3171,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3181,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3218,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3222,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3228,brca_metabric,0.0,1.0,0.0,0,0.0,1.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3235,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3253,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3254,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3266,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3271,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3272,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3275,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3277,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3292,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3295,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3297,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3298,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3300,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3301,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3328,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3329,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3341,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3344,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3351,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3355,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3357,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3360,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3361,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3363,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3367,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3371,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3378,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3379,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3381,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3383,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3386,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3388,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3395,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3396,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3402,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3403,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3412,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3430,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3435,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3436,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3439,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3450,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3452,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3453,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3459,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3462,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3466,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3467,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3470,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3476,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3488,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3490,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3492,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3500,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3502,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3506,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3510,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3525,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3526,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3528,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3530,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3536,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3545,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3548,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3567,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3576,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3582,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3600,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3606,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3614,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3702,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3706,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3707,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3711,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3748,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3752,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3754,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3781,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3797,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3824,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3840,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3850,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3852,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-3854,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3866,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3871,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-3874,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-3978,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4001,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4003,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4005,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4008,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4010,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4011,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4012,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4015,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4024,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4033,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4046,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4059,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4079,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4091,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4098,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4119,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4120,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4126,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4127,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4139,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4140,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4141,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4145,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4146,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4154,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4171,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4173,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4189,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4212,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4222,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4230,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4233,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4234,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4235,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4236,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4250,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4254,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4264,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4270,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4274,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4276,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4278,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4281,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4282,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4283,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4289,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4292,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4293,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4300,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4303,brca_metabric,1.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4306,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4310,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4313,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4317,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4322,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4323,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4324,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4328,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4329,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4332,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4333,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4341,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4342,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4343,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4348,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4350,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4351,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4353,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4357,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4360,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4362,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4368,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4374,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4375,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4381,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4390,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4407,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4408,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4416,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4417,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4418,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4421,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4426,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4442,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4484,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4548,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4557,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4564,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4578,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4593,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4598,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4599,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4602,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4603,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4607,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4616,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4621,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4622,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4623,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4627,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4630,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4633,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4634,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4639,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4640,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4641,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4643,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4644,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4649,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4653,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4654,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4655,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4660,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4661,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4663,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4666,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4667,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4670,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4671,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4675,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4679,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4681,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4682,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4687,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4691,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4692,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4694,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4695,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4696,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4697,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4698,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4704,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4705,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4706,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4707,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4708,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4709,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4710,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4711,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4712,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4714,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4715,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4717,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4718,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4719,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4721,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4722,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4723,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4724,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4725,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4729,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4730,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4731,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4732,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4733,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4737,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4738,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4739,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4741,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4742,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4743,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4744,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4745,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4746,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4749,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4750,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4752,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4757,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4758,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4760,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4762,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4763,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4764,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4769,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4770,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4771,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4779,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4784,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4785,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4787,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4791,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4792,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4793,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4794,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4798,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4801,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4802,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4805,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4809,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4814,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4820,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4822,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4827,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4829,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4832,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4836,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4838,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4843,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4845,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4846,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4849,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4851,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4853,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4855,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4858,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4859,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4860,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4862,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4865,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4867,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4869,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4871,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4872,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4873,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4878,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4879,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4880,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4881,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4882,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4883,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4886,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4887,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4888,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4893,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4894,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4896,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4897,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4898,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4899,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4900,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4904,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4908,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4911,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4912,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4928,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4929,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4930,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4931,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4933,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4938,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4941,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4942,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4944,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4945,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4949,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4952,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-4959,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4961,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4962,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4966,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4967,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4968,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4969,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4970,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4974,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-4976,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4977,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4981,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4982,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4991,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4992,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4993,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4994,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4996,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4998,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-4999,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5001,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5004,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5008,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5011,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5013,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5014,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5015,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5017,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5019,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5020,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5027,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5035,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5039,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5041,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5043,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5045,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5048,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5050,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5052,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5053,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5054,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5057,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5058,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5059,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5060,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5062,brca_metabric,0.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5063,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5065,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5066,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5072,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5073,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5074,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5078,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5079,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5081,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5086,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5088,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5092,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5093,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5097,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5100,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5101,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5102,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5105,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5107,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5110,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5114,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5117,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5118,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5119,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5120,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5121,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5123,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5124,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5126,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5130,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5134,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5135,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5138,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5143,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5145,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5147,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5148,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5152,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5154,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5155,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5157,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5161,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5163,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5164,brca_metabric,0.0,0.0,1.0,0,1.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5166,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5167,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5169,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5173,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5174,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5175,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5179,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5182,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5183,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5184,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5185,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5186,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5189,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5190,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5193,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5195,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5196,brca_metabric,0.0,1.0,0.0,0,0.0,1.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5199,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5200,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5201,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5204,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5205,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5208,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5209,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5211,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5213,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5221,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5223,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5224,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5225,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5226,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5227,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5228,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5229,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5231,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5232,brca_metabric,0.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5233,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5235,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5236,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5244,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5251,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5253,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5256,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5258,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5259,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5264,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5266,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5267,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5268,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5270,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5271,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5272,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5275,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5279,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5280,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5281,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5284,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5287,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5288,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5290,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5292,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5293,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5294,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5295,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5296,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5298,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5299,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5300,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5305,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5306,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5308,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5310,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5311,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5313,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5315,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5318,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5322,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5324,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5326,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5329,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5330,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5332,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5334,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5335,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5338,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5339,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5345,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5346,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5347,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5348,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5360,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5361,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5365,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5366,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5368,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5373,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5377,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5378,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5381,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5382,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5383,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5386,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5388,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5392,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5395,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5396,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5397,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5398,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5399,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5401,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5402,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5404,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5406,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5407,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5409,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5410,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5411,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5412,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5414,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5417,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5418,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5421,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5422,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5424,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5425,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5426,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5427,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5428,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5432,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5434,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5440,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5441,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5442,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5444,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5446,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5450,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5451,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5452,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5453,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5454,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5458,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5465,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5470,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5471,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5472,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5473,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5474,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5475,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5477,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5478,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5481,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5482,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5483,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5484,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5486,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5489,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5491,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5493,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5495,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5498,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5502,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5505,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5510,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5511,brca_metabric,1.0,1.0,0.0,0,0.0,1.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5513,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5519,brca_metabric,0.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5520,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5521,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5525,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5526,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5527,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5529,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5531,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5533,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5534,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5535,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5540,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5543,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5547,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5548,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5549,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5550,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5551,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5552,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5553,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5554,brca_metabric,0.0,1.0,0.0,0,0.0,1.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5558,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5559,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5560,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5563,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5565,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5567,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5571,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5577,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5579,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5580,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5582,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5584,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5588,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5589,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5590,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5591,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5592,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5593,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5597,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5599,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5601,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5602,brca_metabric,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5603,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5614,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5616,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5620,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5622,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5623,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5624,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5626,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5628,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-5629,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5634,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5636,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5638,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5641,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5642,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5645,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5646,brca_metabric,0.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5651,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5652,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5653,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5654,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-5655,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-5656,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6001,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6006,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6007,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6010,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6012,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6014,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6017,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6018,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6019,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6021,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6022,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6023,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6024,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6026,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6029,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6030,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6036,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6039,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6042,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6044,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6047,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6048,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6049,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6050,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6051,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6053,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6055,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6058,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6059,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6060,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6062,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6065,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6068,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6069,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6071,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6077,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6079,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6080,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6083,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6085,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6097,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6098,brca_metabric,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6100,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6101,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6103,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6105,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6107,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6108,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6113,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6114,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6116,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6118,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6122,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6124,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6131,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6133,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6135,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6138,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6143,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6144,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6146,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6150,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6152,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6156,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6157,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6160,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6163,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6164,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6168,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6169,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6171,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6179,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6181,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6182,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6183,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6184,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6185,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6188,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6190,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6192,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6194,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6195,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6200,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6204,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6206,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6207,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6208,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6211,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6212,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6214,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6218,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6223,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6225,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6226,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6228,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6229,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6231,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6232,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6233,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6234,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6237,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6238,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6242,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6245,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6246,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6248,brca_metabric,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6251,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6253,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6263,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6271,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6272,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6273,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6280,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6283,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6286,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6287,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6288,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6300,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6305,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6308,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6314,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6317,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6318,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6322,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6327,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6328,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6329,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6330,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-6334,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-6336,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6337,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6344,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-6359,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7000,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7001,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7002,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7003,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7004,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7005,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7006,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7007,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7008,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7010,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7014,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7015,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7017,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7019,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7020,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7022,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7023,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7024,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7025,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7026,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7027,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7028,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7029,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7030,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7031,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7032,brca_metabric,0.0,1.0,0.0,0,1.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7035,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7036,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7038,brca_metabric,0.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7039,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7040,brca_metabric,0.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7041,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7042,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7043,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7044,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7045,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7046,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7048,brca_metabric,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7050,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7051,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7052,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7053,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7054,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7055,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7056,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7057,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7059,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7061,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7062,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7063,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7065,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7066,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7067,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7068,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7069,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7070,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7071,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7072,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7073,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7074,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7077,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7078,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7079,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7080,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7082,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7083,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7084,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7087,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7088,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7089,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7090,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7091,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7092,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7093,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7094,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7095,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7097,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7101,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7104,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7106,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7107,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7111,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7113,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7114,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7116,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7118,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7119,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7122,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7124,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7132,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7133,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7137,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7141,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7142,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7144,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7145,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7147,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7149,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7150,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7151,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7153,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7154,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7155,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7157,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7158,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7159,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7160,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7162,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7163,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7164,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7165,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7167,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7168,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7170,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7172,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7173,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7174,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7176,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7182,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7185,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7186,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7187,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7189,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7195,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7196,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7197,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7198,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7200,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7201,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7205,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7207,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7208,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7212,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7215,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7217,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7218,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7219,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7220,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7225,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7227,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7228,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7229,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7230,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7232,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7233,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7234,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7235,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7237,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7238,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7241,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7243,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7244,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7250,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7252,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7253,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7254,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7256,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7258,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7260,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7262,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7263,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7264,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7266,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7267,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7268,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7270,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7273,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7275,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7276,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7277,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7278,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7279,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7280,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7281,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7283,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7285,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7286,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7287,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7288,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7289,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7291,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7293,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MB-7294,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7295,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MB-7296,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MB-7298,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0035,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0058,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0059,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0061,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0062,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0063,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0064,brca_metabric,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0065,brca_metabric,1.0,1.0,1.0,0,0.0,0.0,0,HIGH_RISK,7,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0066,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0067,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0068,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0069,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0070,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0072,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0074,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0076,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0077,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0078,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0082,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0084,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0087,brca_metabric,0.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0088,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0089,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0090,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0091,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0092,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0093,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0094,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0095,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0131,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0133,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0134,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0136,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0138,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0139,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0142,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0144,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0145,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0146,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0147,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0148,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0149,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0150,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0152,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0153,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0155,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0156,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0157,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0158,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0160,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0161,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0162,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0163,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0164,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0167,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0170,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0173,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0174,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0175,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0178,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0180,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0181,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0182,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0183,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0184,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0185,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0186,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0188,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0189,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0190,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0191,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0192,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0193,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0194,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0196,brca_metabric,1.0,0.0,0.0,0,1.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0197,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0198,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0199,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0200,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0202,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0203,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0204,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0205,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0206,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0207,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0208,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0209,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0210,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0211,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0212,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0213,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0215,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0216,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0217,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0219,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0220,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0221,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0222,brca_metabric,1.0,1.0,0.0,0,0.0,1.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0223,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0224,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0225,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0226,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0227,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0228,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0229,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0230,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0231,brca_metabric,1.0,1.0,0.0,0,0.0,1.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0232,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0233,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0234,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0235,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0237,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0238,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0239,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0240,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0241,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0242,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0243,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0244,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0245,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0246,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0247,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0248,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0251,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0254,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0255,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0256,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0257,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0273,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0275,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0276,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0279,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0281,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0285,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0286,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0299,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0303,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0304,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0305,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0312,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0313,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0325,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0327,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0328,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0329,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0330,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0331,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0332,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0333,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0334,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0335,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0336,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0337,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0338,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0339,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0340,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0341,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0342,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0343,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0344,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0345,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0346,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0347,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0348,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0349,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0350,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0351,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0352,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0353,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0354,brca_metabric,0.0,0.0,1.0,0,0.0,0.0,0,LOW_RISK,2,ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0355,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0356,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0357,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0358,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0359,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0360,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0362,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0363,brca_metabric,1.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0364,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0367,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0368,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0369,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0370,brca_metabric,0.0,1.0,0.0,0,0.0,1.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0371,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0373,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0375,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0376,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0377,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0380,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0381,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0382,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0383,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0384,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0385,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0386,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0387,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0388,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0389,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0390,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0391,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0392,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0393,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0394,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0395,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0396,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0397,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0399,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0400,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0404,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0406,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0407,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0456,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0466,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0468,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0490,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0508,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0510,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0516,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0525,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0602,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0646,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0673,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0685,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0689,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0693,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0694,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0695,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0696,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0697,brca_metabric,0.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0698,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0699,brca_metabric,1.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0700,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0701,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0702,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0703,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0704,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0706,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0707,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0708,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0709,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0710,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0711,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0713,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0714,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0715,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0716,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0718,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0721,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T0723,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0725,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0726,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0737,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0824,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0877,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0883,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0911,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T0927,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T0951,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1000,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1020,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1047,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1134,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1138,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1161,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1191,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1203,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1213,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1223,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1240,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1248,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1259,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1264,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1269,brca_metabric,0.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1270,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1278,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1282,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T1284,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1285,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1286,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1287,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1288,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1290,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T1291,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1292,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1293,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1298,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1300,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1301,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1303,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1306,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1307,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1309,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1310,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1312,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1314,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1326,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1329,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1366,brca_metabric,1.0,0.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1454,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1503,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1515,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1516,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1517,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1522,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1526,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1527,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1548,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1549,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1560,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,4,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1561,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T1582,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1583,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T1605,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1633,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1659,brca_metabric,0.0,1.0,0.0,0,0.0,1.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1706,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1774,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1800,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1829,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T1847,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1865,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T1872,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1945,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1962,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1971,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1973,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1983,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T1985,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T1991,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2018,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T2030,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2031,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2043,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2055,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2064,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2065,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T2066,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2068,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2075,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T2076,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2083,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2084,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2085,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2086,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2090,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2094,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2095,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2097,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2104,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2105,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T2106,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2107,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2115,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2117,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T2118,brca_metabric,1.0,0.0,0.0,0,0.0,1.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2127,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2128,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2129,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T2150,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2153,brca_metabric,0.0,1.0,1.0,0,0.0,0.0,0,MEDIUM_RISK,4,PIK3CA mutation (bypass HER2 signaling); ERBB2 mutation (may reduce ADC binding),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2167,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2178,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2189,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2190,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2191,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2206,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2212,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2391,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,LOW,2,ESR1 wild-type (no endocrine resistance); PTEN loss (endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2392,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2398,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2403,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2404,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2405,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T2406,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2407,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2408,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2409,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2410,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2412,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2413,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2414,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2416,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2419,brca_metabric,0.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,0,,LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2420,brca_metabric,1.0,0.0,0.0,0,0.0,0.0,0,LOW_RISK,3,TP53 mutation (impaired DNA damage response),LOW_RISK,0,,MEDIUM,3,ESR1 wild-type (no endocrine resistance),MEDIUM,2,No tubulin mutations detected
MTS-T2423,brca_metabric,1.0,1.0,0.0,0,1.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T2424,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
MTS-T2426,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2428,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2429,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2430,brca_metabric,0.0,1.0,0.0,0,0.0,0.0,0,LOW_RISK,2,PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),HIGH,4,TP53 wild-type (better microtubule targeting); No tubulin mutations detected
MTS-T2431,brca_metabric,1.0,1.0,0.0,0,0.0,0.0,0,MEDIUM_RISK,5,TP53 mutation (impaired DNA damage response); PIK3CA mutation (bypass HER2 signaling),LOW_RISK,0,,MEDIUM,5,ESR1 wild-type (no endocrine resistance); PIK3CA mutation (PI3K inhibitor candidate),MEDIUM,2,No tubulin mutations detected
